Arcus Biosciences (RCUS) Prices 11M Share Common Offering at $27.50/Sh

Arcus Biosciences (RCUS) Commences Underwritten Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that it has commenced an underwritten public offering of its common stock. The company intends to grant the underwriters a 30-day option to purchase up... More

Arcus Biosciences (RCUS) PT Raised to $48 at Wedbush, Following Important Business Update

Wedbush analyst Robert Driscoll raised the price target on Arcus Biosciences (NYSE: RCUS) to $48.00 (from $40.00) while maintaining a Outperform rating.

Pre-Open Stock Movers 05/27: (HTZ) (PHUN) (MRSN) (STNE) (CPIX) (HTBX) (SAVE) (more...)

Today's Pre-Open Stock Movers:

Hertz Global Holdings, Inc. (NYSE: HTZ) +58%; announced over the weekend it and certain of its U.S. and Canadian subsidiaries have filed voluntary petitions for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Phunware (NASDAQ: PHUN) +38%; announced today its strategic relationship with American Made Media Consultants on the development, launch and ongoing management and evolution of the Trump-Pence... More

Gilead Sciences (GILD), Arcus Biosciences (RCUS) Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcuss pipeline. The agreement will also provide ongoing funding to support Arcuss research and development programs.

Arcus is building an extensive and diverse portfolio of investigational products that target important mechanisms involved in tumor evasion of the immune system, as well as developing drug candidates... More